Navigation Links
Cleveland Clinic researchers honored for contributions to science and technology
Date:2/24/2011

Wednesday, February 23, 2011 Cleveland Three Cleveland Clinic researchers were recently named as Fellows of the American Association for the Advancement of Science (AAAS), which seeks "to advance science, engineering, and innovation throughout the world for the benefit of all people."

The following individuals were recognized for their contributions to science and technology at the Fellows Forum on February 19, 2011, during the AAAS Annual Meeting in Washington, D.C.:

  • Thomas A. Hamilton, Ph.D., Chair, Immunology, Lerner Research Institute;
  • Qing Kenneth Wang, Ph.D., Molecular Cardiology, Lerner Research Institute;
  • Ram Ganapathi, Ph.D., Translational Hematology and Oncology Research, Taussig Cancer Institute.

Hamilton and Wang were elected Fellows under the AAAS's Section on Medical Sciences, and Ganapathi was elected as a Fellow under the Section on Pharmaceutical Sciences.

AAAS states: "Election as a Fellow of AAAS is an honor bestowed upon members by their peers. Fellows are recognized for meritorious efforts to advance science or its applications."

Hamilton was recognized for contributions to the understanding of inflammatory processes, particularly at the level of cytokine and chemokine gene expression and mRNA stabilization. "We continue to work toward definition of the molecular events that control the expression of inducible genes during the initiation and resolution of both inflammation and cell stress responses," Hamilton said. "Specifically these studies focus upon alterations in transcription and mRNA metabolism that can produce significant changes in levels of gene products that have important roles in coordinating the outcome of injury."

Wang was recognized for the discovery of the first gene for the lethal heart rhythm disorder Brugada syndrome, identification of mechanisms of channelopathies, and fundamental contributions to the field of arrhythmias, seizures, and sudden death. "We have identified nine genes that cause various cardiovascular and neurological diseases," said Wang, who is also Professor of Molecular Medicine at Cleveland Clinic Lerner College of Medicine and Professor of Genetics at Case Western Reserve University.

Ganapathi was recognized for contributions in the field of cancer pharmacology, molecular prognostication and anti-cancer drug development. "We continue our work on clinically active anti-tumor drugs to determine the mechanism of action and pathways of resistance, so that pharmacogenomics and targeted approaches can be exploited to maximize efficacy and reduce toxicity of chemotherapy in the treatment of cancer," said Ganapathi, who is Director of Clinical Pharmacology at the Cleveland Clinic Taussig Cancer Institute and Professor of Medicine in the Cleveland Clinic Lerner College of Medicine.


'/>"/>

Contact: Dan Doron
dorond@ccf.org
216-312-0428
Lerner Research Institute
Source:Eurekalert

Related biology news :

1. Draft sequence of Neandertal genome wins the 2010 AAAS Newcomb Cleveland Prize, supported by Affymetrix
2. Cleveland Museum of Natural History scientist announces new horned dinosaur
3. Cleveland Clinic, CWRU dental researcher finds switch that turns on the spread of cancer
4. Preview of oral presentations at the 1st IOF-ESCEO Pre-Clinical Symposium
5. Press registration open for clinical nutrition conference
6. Clinical Benefits of Zimmers DeNovo® NT Natural Tissue Graft in First Surgery Documented in Peer-Reviewed Publication
7. Media alert: ACMG 2011 Clinical Genetics Meeting -- press registration is now open
8. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
9. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
10. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
11. Cornell Dots that light up cancer cells go into clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... Mar 23, 2017 Research and Markets ... Markets" report to their offering. ... The Global Market for ... in 2016 at a CAGR of 8.9%, ... non-energetic bioproducts into seven major product segments: bio-derived chemicals, biofuels, ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
Breaking Biology Technology: